Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.53 |
| ▸ | PPARD | Q03181 | 2/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.48 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | NQO2 | P16083 | 4/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3412786 | 1.00 | FFAR1 (0.53) | FFAR1PPARDMTNR1AMAOBHRH3 | |
| SCHEMBL3410356 | 0.88 | FFAR1 (0.52) | FFAR1PPARDMTNR1AMAOBNQO2 | |
| SCHEMBL3410358 | 0.88 | FFAR1 (0.52) | FFAR1PPARDMTNR1AMAOBNQO2 | |
| SCHEMBL3413435 | 0.88 | FFAR1 (0.52) | FFAR1PPARDMTNR1AMAOBNQO2 | |
| SCHEMBL12394485 | 0.81 | MTNR1A (0.70) | MTNR1ANQO2MTNR1B | |
| SCHEMBL3962234 | 0.81 | PPARD (0.74) | FFAR1PPARD | |
| SCHEMBL3965769 | 0.81 | PPARD (0.74) | FFAR1PPARD | |
| SCHEMBL3962238 | 0.81 | PPARD (0.74) | FFAR1PPARD | |
| SCHEMBL1746574 | 0.78 | HRH3 (0.53) | MAOBHRH3KDM1AMAOA | |
| SCHEMBL3412521 | 0.78 | PPARG (0.49) | MAOBHRH3FAAHKDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450522-B2 | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20100298367-A1 | Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders | AMGEN INC. | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298367-A1 | Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders | PC, GOT2, CS | FFAR1 171/4885PPARD 159/4885MTNR1A 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.